Ekta Batra ✓

@ekta_batra · Mumbai · joined 14 Apr 2009

Editor, Pharmaceutical and Health, CNBC TV18. Reporting, Analysing Pharma & Health since 2008. Tweets personal. Coffee & puppy addict. Myopic bt not in my views

71 430Followers

739Following

6 696Posts total

51.7KViews on collected posts

Postingan terbaru

Ekta Batra ✓@ekta_batra23 Sep

Neuland Labs. A stock that has risen 1.3x in 5 yrs and 50% this year. Cashing in on the complex niche cdmo opportunity the co guides for medium term growth of 20% and margins 25%. Listen in. 10.1K views · 84 likes · 8 reposts · 4 replies Open on X →

Ekta Batra ✓@ekta_batra23 Sep

@ekta_batra @CNBCTV18Live Pump it 317 views · 2 likes · 0 reposts · 0 replies Open on X →

Ekta Batra ✓@ekta_batra22 Sep

@ekta_batra @CNBCTV18Live Has the interview being telecasted ? @ekta_batra @CNBCTV18Live 736 views · 0 likes · 0 reposts · 1 replies Open on X →

Ekta Batra ✓@ekta_batra22 Sep

Interviewed Saharsh Davuluri of Neuland Labs at their new peptide facility in Hyderabad. For those who want to understand the opportunity from the peptide biz, China plus one and why Neuland has such lumpy numbers...this interview is for you. Do tune in to @CNBCTV18Live for more.

19.4K views · 161 likes · 9 reposts · 2 replies Open on X →

Ekta Batra ✓@ekta_batra10 Sep

Thank you ! 2.4K views · 6 likes · 0 reposts · 0 replies Open on X →

Ekta Batra ✓@ekta_batra9 Sep

Biocon , a very informative interview by @ekta_batra from CNBC on their Malaysia plant , Insulin , Plan on Debt and Biosmilars portfolio , some very good questions Link: https://t.co/lPfvBkeddP 9.3K views · 24 likes · 2 reposts · 3 replies Open on X →

Ekta Batra ✓@ekta_batra8 Sep

What’s next for Biocon? I spoke to Biocon’s CEO & MD Shreehas Tambe at its Malaysian facility about the company’s next phase of growth — from insulin and biosimilars to GLP-1s, margins, debt reduction, US opportunities and the company’s long-term strategy. Listen in. 2K views · 6 likes · 0 reposts · 0 replies Open on X →

Ekta Batra ✓@ekta_batra8 Sep

#CNBCTV18 Global Exclusive | CNBC-TV18 At Biocon’s Malaysia Unit MD & CEO, Shreehas Tambe To @CNBCTV18News - Expect double-digit revenue growth for biosimilars to continue - Should hit $1 bn target for biosimilar business soon - Change in biosimilar policies in the US will aid h

7:36

7.4K views · 4 likes · 0 reposts · 0 replies Open on X →

Ekta Batra ✓@ekta_batra30 Apr 2022

What a week. 2nd award in a week! Been awarded the Best continuing coverage by a reporter at the ENBA Broadcast awards. Bronze. Couldn't have done it without the fabulous team @cnbctv18india ❤️ https://t.co/ZBeD3bDpfV

0 views · 831 likes · 17 reposts · 112 replies Open on X →

Dibandingkan akun berukuran sama

8 postingan dari 90 hari terakhir, dibandingkan dengan rentang 10K–100K pengikut. tampil luas, tetapi sedikit penonton yang merespons.

Median tayangan4 910akun ini924median untuk 10K–100K

Jangkauan, %6.87%akun ini3.62%median untuk 10K–100K

Interaksi, %0.31%akun ini1.52%median untuk 10K–100K

Metrik	Akun ini	Median untuk 10K–100K	Rasio
Median tayangan per postingan	4 910	924	5.31×
Jangkauan (tayangan ÷ pengikut)	6.87%	3.62%	1.90×
Tingkat interaksi	0.31%	1.52%	0.20×

Akun lain pada rentang ini → Bandingkan dengan akun lain → Bagaimana tolok ukur ini disusun →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

7.4K8 Sep

9.3K9 Sep

2.4K10 Sep

19.4K22 Sep

736

31723 Sep

10.1K

Last 8 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.07%8 Sep

0.29%

0.32%9 Sep

0.25%10 Sep

0.90%22 Sep

0.14%

0.63%23 Sep

0.96%

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.

What the audience does

Likes67.5%287 in total

Reposts4.5%19 in total

Replies2.4%10 in total

Quotes1.4%6 in total

Bookmarks24.2%103 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.